Evidence map›Paper›PMID 38903492›Full record

ArticleFrontiers in immunology2024

Heart immunoengineering by lentiviral vector-mediated genetic modification during normothermic

Katharina Schmalkuche, Tamina Rother, Jonathan M Burgmann, Henrike Voß, Klaus Höffler, Günes Dogan, Arjang Ruhparwar, Jan D Schmitto, Rainer Blasczyk, Constanca Figueiredo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. International journal of biological sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Immune Checkpoint Inhibitor Therapy for Kidney Transplant Recipients - A Review of Potential Complications and Management Strategies.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Katharina Schmalkuche *Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Tamina Rother *Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Jonathan M Burgmann *Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Henrike VoßInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Klaus HöfflerDepartment of Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Günes DoganDepartment of Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Arjang RuhparwarDepartment of Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Jan D SchmittoDepartment of Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Rainer BlasczykInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Constanca FigueiredoInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart transplantation is associated with major hurdles, including the limited number of available organs for transplantation, the risk of rejection due to genetic discrepancies, and the burden of immunosuppression. In this study, we demonstrated the feasibility of permanent genetic engineering of the heart during

Indexed as

Genetic VectorsHeart TransplantationHistocompatibility Antigens Class ILentivirusAnimalsbeta 2-MicroglobulinCytokinesEndothelial CellsGenetic EngineeringGraft SurvivalHistocompatibility Antigens Class IIHumansMyocytes, CardiacNuclear ProteinsPerfusionRNA, Small Interferingbeta 2-MicroglobulinCytokinesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIMHC class II transactivator proteinNuclear ProteinsRNA, Small Interferingswine leukocyte antigenTrans-Activatorsgenetic modificationheart immunoengineeringlentiviral vectornormothermic ex vivo perfusiontransplantation

Identifiers

PMID38903492
PMCPMC11188324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.